The authors suppose that expected advances in creation of highly selective (i.e., low toxic for normal cells) inhibitors of certain HSP70—co-factor interactions along with further development/improvement of pharmacological systems for formulation and targeted delivery of therapeutic agents will help to achieve the sought-after method for curative targeting HSP70 in breast tumors. The gene discussed is HSPA1A; the disease is breast neoplasm.